CalciMedica, Inc. Common Stock (CALC)vsVertex Pharmaceuticals Inc (VRTX)
CALC
CalciMedica, Inc. Common Stock
$0.99
+24.62%
HEALTHCARE · Cap: $12.89M
VRTX
Vertex Pharmaceuticals Inc
$499.65
+1.69%
HEALTHCARE · Cap: $124.70B
Smart Verdict
WallStSmart Research — data-driven comparison
VRTX leads profitability with a 35.5% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 68/100 (B-).
CALC
Avoid19
out of 100
Grade: F
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CALC.
Margin of Safety
+48.3%
Fair Value
$949.55
Current Price
$499.65
$449.90 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CALC
CALC has a balanced fundamental profile.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : CALC
The primary concerns for CALC are Revenue Growth, EPS Growth, Market Cap.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
CALC profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
CALC carries more volatility with a beta of 1.24 — expect wider price swings.
VRTX is growing revenue faster at 7.8% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 19/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CalciMedica, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies that modulate calcium-dependent pathways to address acute and chronic health issues. Its lead candidate, CM4620, targets severe muscle cramps in patients with sickle cell disease, highlighting the company's commitment to tackling critical unmet medical needs. With a proprietary technology platform and a well-defined pipeline of novel calcium modulators, CalciMedica is well-positioned for growth. The company is supported by a seasoned management team and strategic partnerships aimed at accelerating its clinical development, making it a noteworthy investment opportunity in the biopharmaceutical landscape.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?